Recombinant Monkey IL37/IL1F7 Protein, N-His

Description of Recombinant Monkey IL37/IL1F7 Protein, N-His

Introduction

Recombinant proteins are proteins that are produced through genetic engineering techniques, allowing for the production of large quantities of specific proteins for research and therapeutic purposes. One such protein is Recombinant Monkey IL37/IL1F7 Protein, which has gained attention for its potential role in modulating the immune response and its potential therapeutic applications.

Structure of Recombinant Monkey IL37/IL1F7 Protein

Recombinant Monkey IL37/IL1F7 Protein is a member of the interleukin-1 family of cytokines, which play important roles in regulating the immune response. It is a 17 kDa protein that is composed of 152 amino acids and has a similar structure to other members of the IL-1 family. It contains a signal peptide, a propeptide, and a mature protein region. The mature protein region is further divided into three subdomains: the N-terminal domain, the central domain, and the C-terminal domain.

Activity of Recombinant Monkey IL37/IL1F7 Protein

Recombinant Monkey IL37/IL1F7 Protein is a potent anti-inflammatory cytokine that has been shown to suppress the immune response in various disease models. It exerts its effects by binding to the IL-18 receptor alpha chain and the IL-1 receptor accessory protein, leading to the activation of a signaling pathway that results in the inhibition of pro-inflammatory cytokines. This activity has been demonstrated in both in vitro and in vivo studies, making Recombinant Monkey IL37/IL1F7 Protein a promising candidate for therapeutic use.

Application of Recombinant Monkey IL37/IL1F7 Protein

The potential therapeutic applications of Recombinant Monkey IL37/IL1F7 Protein are vast and have been explored in various disease models. One area of interest is in the treatment of inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. In these conditions, the immune response is dysregulated, leading to chronic inflammation. Recombinant Monkey IL37/IL1F7 Protein has been shown to suppress this inflammation and may offer a new therapeutic approach for these diseases.

Another potential application of Recombinant Monkey IL37/IL1F7 Protein is in the treatment of autoimmune diseases. Autoimmune diseases occur when the immune system mistakenly attacks healthy cells and tissues in the body. Recombinant Monkey IL37/IL1F7 Protein has been shown to have immunosuppressive effects and may be able to modulate the immune response in these conditions, leading to improved outcomes for patients.

In addition, Recombinant Monkey IL37/IL1F7 Protein has been studied for its potential role in cancer therapy. It has been shown to inhibit the growth and proliferation of cancer cells in various types of cancer, such as lung cancer and breast cancer. Its anti-inflammatory effects may also contribute to its potential anti-cancer activity by reducing inflammation in the tumor microenvironment.

Antigen-specific Applications

Recombinant Monkey IL37/IL1F7 Protein has also been studied for its potential as an antigen-specific therapy. In this approach, the protein is used as an antigen to stimulate an immune response against specific antigens, such as tumor antigens. This has been explored in the development of cancer vaccines, where Recombinant Monkey IL37/IL1F7 Protein is used as a carrier to deliver tumor-specific antigens and stimulate an immune response against the cancer cells.

Conclusion

In summary, Recombinant Monkey IL37/IL1F7 Protein is a promising protein with potent anti-inflammatory and immunomodulatory effects. Its potential therapeutic applications in inflammatory and autoimmune diseases, as well as cancer, make it a promising candidate for further research and development. Additionally, its potential as an antigen-specific therapy adds to its versatility and potential for use in various disease contexts. Continued research on Recombinant Monkey IL37/IL1F7 Protein may lead to the development of new treatments for a range of diseases,